Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

NCT ID: NCT00833079

Last Updated: 2014-01-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 500 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2010-03-31

Brief Summary

The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment 0.1%, manufactured by Taro Pharmaceuticals Inc. and Protopic® (tacrolimus), 0.1% topical ointment (Astellas Pharma US, Inc.) and to show superiority over vehicle in the treatment of moderate to severe atopic dermatitis.

The secondary objectives are to compare the adverse event (AE) profiles of the two ointments and to investigate their systemic absorption at steady state.

Conditions

Atopic Dermatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Tacrolimus 0.1% Taro

Tacrolimus 0.1% manufactured by Taro applied for 14 days

Group Type: EXPERIMENTAL

Tacrolimus 0.1% manufactured by Taro

Intervention Type: DRUG

Treatment applied as a thin layer to target area twice daily for 14 days

Protopic - Tacrolimus 0.1%

Protopic, Tacrolimus 0.1% applied for 14 days

Group Type: ACTIVE_COMPARATOR

Protopic - Tacrolimus 0.1%

Intervention Type: DRUG

Treatment applied as a thin layer to target area twice daily for 14 days

Vehicle

Tacrolimus vehicle applied for 14 days

Group Type: PLACEBO_COMPARATOR

Tacrolimus Vehicle manufactured by Taro

Intervention Type: DRUG

Treatment applied as a thin layer to target area twice daily for 14 days

Interventions

Tacrolimus 0.1% manufactured by Taro

Treatment applied as a thin layer to target area twice daily for 14 days

Intervention Type: DRUG

Protopic - Tacrolimus 0.1%

Treatment applied as a thin layer to target area twice daily for 14 days

Intervention Type: DRUG

Tacrolimus Vehicle manufactured by Taro

Treatment applied as a thin layer to target area twice daily for 14 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or non-pregnant, non-lactating female, 18 years of age or older.
• Patient has documented evidence that they have been unresponsive to alternative more traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient.
• If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives).
• Have confirmed diagnosis of atopic dermatitis using the diagnostic features as described by Hanifin and Rajka.
• Have an IGSA score of 3 (moderate) or 4 (severe)
• Have an affected Body Surface Area (BSA) of at least 20%
• Have a minimum Eczema Area and Severity Index (EASI) score of at least 15

Exclusion Criteria

• Mild atopic dermatitis as defined by IGSA score of 0 (clear), 1 (almost clear), or 2 (mild) OR %BSA affected less than 20% OR EASI Score of less than 15.
• Clinically infected atopic dermatitis at the baseline visit. Tacrolimus is not indicated for the treatment of clinically infected atopic dermatitis
• Any dermatological condition other than atopic dermatitis that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis
• Females who are pregnant, lactating or likely to become pregnant during the study.
• History of allergy or sensitivity to tacrolimus, pimecrolimus, any macrolides such as clindamycin erythromycin
• Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressants, including but not limited to human immunodeficiency virus (HIV) and cancer.
• Use of any nonsteroidal immunosuppressants
• Regular use of intranasal or inhaled corticosteroids, greater than the equivalent of 2 mg of prednisone/day, within 14 days of the first dosing day.
• Use of non-sedating histamines are not allowed for at least 7 days prior to the first dosing day or throughout the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Pharmaceutical Industries, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

TACR-0707

Identifier Type: -

Identifier Source: org_study_id